Free Trial

Acumen Pharmaceuticals Q4 2022 Earnings Report

Acumen Pharmaceuticals logo
$1.65 +0.04 (+2.48%)
As of 01/17/2025 04:00 PM Eastern

Acumen Pharmaceuticals EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Acumen Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acumen Pharmaceuticals Announcement Details

Quarter
Q4 2022
Time
Before Market Opens

Conference Call Resources

Acumen Pharmaceuticals Earnings Headlines

Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Acumen announces Phase 1 INTERCEPT-AD study publication
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic
See More Acumen Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acumen Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acumen Pharmaceuticals and other key companies, straight to your email.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

View Acumen Pharmaceuticals Profile

More Earnings Resources from MarketBeat